ישראל - עברית - Ministry of Health

medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 60 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.

ישראל - עברית - Ministry of Health

medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 90 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.

ישראל - עברית - Ministry of Health

medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 120 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.

ישראל - עברית - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - תמיסה להזרקה - pasireotide as diaspartate 0.3 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

ישראל - עברית - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - תמיסה להזרקה - pasireotide as diaspartate 0.6 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

ישראל - עברית - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - תמיסה להזרקה - pasireotide as diaspartate 0.9 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.05 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.5 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome. vipomas . glucagonomas . gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.